Skip to main content
. 2022 Feb 8;19:44. doi: 10.1186/s12974-022-02404-2

Table 5.

Sample classification after LDA to discriminate between CSF samples from patients with Relapse–remitting multiple sclerosis (RRMS) vs. other diseases (inflammatory and non-inflammatory) of the CNS (INF and N-INF) after data reduction with PCA.

Disease Predicted Group Membershipb.c Total
RRMS INF and N-INF
Original
 Count RRMS 55 14 69
INF and N-INF 11 58 69
 % RRMS 79.7 20.3 100
INF and N-INF 15.9 84.1 100
Cross-validateda
 Count RRMS 55 14 69
INF and N-INF 11 58 69
 % RRMS 79.7 20.3 100
INF and N-INF 15.9 84.1 100

aCross-validation is done only for those sets of samples analyzed. In cross-validation, each sample is classified by the functions derived from all samples other the one under analysis

b81.9% of original grouped samples correctly classified

c81.9% of cross-validated grouped samples correctly classified